Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Total Current Liabilities (2020 - 2026)

Aura Biosciences filings provide 7 years of Total Current Liabilities readings, the most recent being $16.7 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 37.35% to $16.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $16.7 million through Mar 2026, up 37.35% year-over-year, with the annual reading at $18.4 million for FY2025, 23.27% up from the prior year.
  • Total Current Liabilities hit $16.7 million in Q1 2026 for Aura Biosciences, down from $18.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $18.8 million in Q3 2025 and bottomed at $5.0 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $11.9 million, with a median of $10.9 million recorded in 2023.
  • The largest annual shift saw Total Current Liabilities skyrocketed 70.88% in 2022 before it grew 9.33% in 2023.
  • Aura Biosciences' Total Current Liabilities stood at $10.5 million in 2022, then grew by 18.17% to $12.4 million in 2023, then increased by 20.68% to $14.9 million in 2024, then grew by 23.27% to $18.4 million in 2025, then fell by 9.12% to $16.7 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Total Current Liabilities are $16.7 million (Q1 2026), $18.4 million (Q4 2025), and $18.8 million (Q3 2025).